CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neuphoria Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neuphoria Therapeutics Inc
100 Summit Dr
BURLINGTON, MA  01803  United States Ticker: BNOXBNOX
This company ceased filing statements with the SEC on 12/23/2024.
Business Summary
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the a7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20246/30/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board AlanFisher 71 7/1/2023 9/1/2016
President, Chief Executive Officer, Director SpyridonPapapetropoulos 52 1/5/2023 1/5/2023
Chief Financial Officer Timothy M.Cunningham 62 7/1/2023 7/1/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Eclipse Therapeutics Inc. 11575 Sorrento Valley Road San Diego CA United States
Neuphoria Therapeutics Inc - ADR 100 Summit Dr BURLINGTON MA United States

Business Names
Business Name
Bionomic Ltd.
BNO
BNOX
Eclipse Therapeutics Inc.
Iliad Chemicals Pty Limited
Prestwick Chemical

General Information
Number of Employees: 8 (As of 6/30/2024)
Outstanding Shares: 1,924,808,444 (As of 12/31/2023)
Shareholders: 3,500
Stock Exchange: ASX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025